{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"75c7c081-3b2a-5f62-aead-766ba5534a36","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 1af9409d-afce-49cc-8fcd-9c0d74aebeb7 --><h2>Changes</h2><!-- end field 1af9409d-afce-49cc-8fcd-9c0d74aebeb7 -->","summary":null,"htmlStringContent":"<!-- begin item 0a155ca9-be6c-4883-bbad-f6c97b19d1a8 --><!-- begin field d5f7a9fd-f058-48e9-901e-84052ba52e69 --><p><strong>March 2020 </strong>— Minor update. Minor update to the sections on Definition, and Causes and risk factors. Links to the BMJ review article have been amended. </p><p><strong>January 2020 </strong>— reviewed. A literature search was conducted in December 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to clinical recommendations have been made. </p><!-- end field d5f7a9fd-f058-48e9-901e-84052ba52e69 --><!-- end item 0a155ca9-be6c-4883-bbad-f6c97b19d1a8 -->","topic":{"id":"07820562-ab2f-5ea0-9097-3e6e5a62bec4","topicId":"3c0e3637-8623-4aa4-9bdf-83c4ead61135","topicName":"Superficial vein thrombosis (superficial thrombophlebitis)","slug":"superficial-vein-thrombosis-superficial-thrombophlebitis","lastRevised":"Last revised in March 2020","chapters":[{"id":"a5f3a42e-3e23-59d7-83fb-fd26995ebf74","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ceec510-5b3b-59b2-be08-fde928defc1e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8b0cc395-7b80-5e19-a891-b27b1d88c9f3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"75c7c081-3b2a-5f62-aead-766ba5534a36","slug":"changes","fullItemName":"Changes"},{"id":"fcc6e0b2-bfab-56d2-a1e0-57e5f3f6c19a","slug":"update","fullItemName":"Update"}]},{"id":"6da7aa90-c506-5e57-baed-74b22c09af0a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8a802f98-487d-5c7e-829e-4a9e669fe875","slug":"goals","fullItemName":"Goals"},{"id":"7dff5216-bc4a-529e-854f-a128cb8b54ca","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"999e411a-0346-5c64-aa2d-eba133633715","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fed9fa0e-2eb0-5385-b244-1efe9fad43ce","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"58585f51-d63a-5cf7-bd5e-f14b6dd9c02a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"62ad8730-5197-5854-acff-ffd86c7f8b92","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5d82d4b3-7ef8-52e7-a668-a65cc11d7bf7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"63f70d2c-b895-556e-8108-242a922f573d","slug":"definition","fullItemName":"Definition"},{"id":"8bfc3751-dc6d-58d5-9548-38ebf176bc48","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"8b1679ef-efa4-5e5e-8690-815334d03623","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b23bb9bc-355d-5db3-909c-ba53a4e4ed95","slug":"complications","fullItemName":"Complications"},{"id":"898b7fad-5295-5eef-991c-921d6b584b9c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a7a8c85c-9ce4-5f12-a1f5-23a4ebba755d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"f7b2717f-67b0-51d3-802e-6289738de5fd","slug":"assessment","fullItemName":"Assessment"},{"id":"c4ead320-38b8-564e-b12e-14547b74132b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"feb9b5f1-73aa-5b36-adca-1c0cf461f9fa","fullItemName":"Management","slug":"management","subChapters":[{"id":"b2e8f26a-d211-5c11-8c71-c772eea8dde7","slug":"management-of-superficial-vein-thrombosis","fullItemName":"Scenario: Management of superficial vein thrombosis"}]},{"id":"ce1a244a-7eef-554a-b0fd-97c7358b1c5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"98221bb6-71ac-5332-8985-2100a5306385","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3b6f9e44-2ba1-5f2a-a188-d838e155e461","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"21be8a1b-6557-5a82-8b2c-b0e11bd94c6f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"71a14a91-6970-576c-a048-a5e79a477304","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6bee233-b8a0-577f-874c-2612e21a7dff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fd0ecbc9-ffa5-52d9-839e-435308bda796","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ccd8f8d7-dbcb-5110-ba6c-fe88bca09f07","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8b0cc395-7b80-5e19-a891-b27b1d88c9f3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"733dd477-699d-592c-a40f-a19061e6ada8","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field b55a436d-b64a-472b-884e-0882e417a333 --><h3>Previous changes</h3><!-- end field b55a436d-b64a-472b-884e-0882e417a333 -->","summary":null,"htmlStringContent":"<!-- begin item 5f36190a-c8ba-4416-8c00-fe62126d258c --><!-- begin field 80a8ab00-f8d5-46ff-9a68-42d580bd3a49 --><p><strong>May 2017 </strong>— minor update. Correction made to supporting information on fondaparinux.</p><p><strong>December 2016 </strong>— minor update. The dose of clarithromycin for people with severe renal impairment has been clarified, in line with the manufacturer's Summary of Product Characteristics.</p><p><strong>July 2015 </strong>— minor update. The information on the concurrent use of clarithromycin or erythromycin with statins has been clarified.</p><p><strong>May 2014 </strong>— reviewed. A literature search was conducted in April 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes have been made to the recommendations; however, fondaparinux has now been included as a drug option for deep vein thrombosis (DVT) prophylaxis in people with superficial thrombophlebitis who are judged to be at increased risk of a DVT. Additional sections on the prognosis and complications of superficial thrombophlebitis as well as antibiotics prescribing information have also been added.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (<a data-hyperlink-id=\"bc9c04fc-c818-489b-a493-a98d00667d29\" href=\"http://www.medicines.org.uk/\">www.medicines.org.uk</a>) have been updated.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>March 2011 </strong>— minor update to the <em>Supporting evidence </em>section on subcutaneous heparins. Issued in March 2011.</p><p><strong>December 2008 to March 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. The only substantive change to the recommendations is to consider referral for subcutaneous low molecular weight heparin when there is an increased risk of venous thromboembolism.</p><p><strong>July to September 2005 </strong>— reviewed. Validated in December 2005 and issued in February 2006.</p><p><strong>July 2005 </strong>— updated to include prescribing information for compression stockings. Issued in July 2005.</p><p><strong>April 2002 </strong>— reviewed. Validated in June 2002 and issued in July 2002.</p><p><strong>February 1999 </strong>— written. Validated in April 1999 and issued in May 1999.</p><!-- end field 80a8ab00-f8d5-46ff-9a68-42d580bd3a49 --><!-- end item 5f36190a-c8ba-4416-8c00-fe62126d258c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}